Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating. We conducted a retrospective study on patients with conf...

Full description

Bibliographic Details
Main Authors: Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello, Biagio Pinchera, Riccardo Villari, Emilia Trucillo, Luigi Ametrano, Ludovica Fusco, Giuseppe Castaldo, Antonio Riccardo Buonomo, Federico II COVID Team
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Vaccines
Subjects:
COVID-19
SARS-CoV-2
molnupiravir
nirmatrelvir/ritonavir
hospitalization
adverse drug reactions
Online Access:https://www.mdpi.com/2076-393X/10/10/1731

Similar Items

Similar Items